Cancer risk assessment and cancer prevention: Promises and challenges

Cancer Prevention Research

Volumn 1, Issue 4, 2008, Pages 229-232

  Reid, Brian J ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MODEL; DISEASE COURSE; DRUG RESISTANCE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; METHODOLOGY; MOLECULAR EVOLUTION; NEOPLASM; PRECANCER; REVIEW; RISK ASSESSMENT;

DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EVOLUTION, MOLECULAR; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; POLYMORPHISM, GENETIC; PRECANCEROUS CONDITIONS; RISK ASSESSMENT;

EID: 61549091224     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0113     Document Type: Note

References (40)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
2. ACS Cancer Statistics 2008. Available from: http:// www.acs.org.
3. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293: 2095-101.
4. Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl Cancer Inst 2006;98: 748-56.
5. Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 2003;52:1081-4.
6. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997;278:1073-7.
7. Etzioni R, Urban N, Ramsey S, et al. The Case for Early Detection. Nat Rev Cancer 2003;3:1-10.
8. Shaheen NJ, Green B, Medapalli RK, et al. The perception of cancer risk in patients with prevalent Barrett's esophagus enrolled in an endoscopic surveillance program. Gastroenterology 2005;129: 429-36.
9. Shaheen NJ, Dulai GS, Ascher B, Mitchell KL, Schmitz SM. Effect of a new diagnosis of Barrett's esophagus on insurance status. Am J Gastroenterol 2005;100:577-80.
10. Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther 2008;27:316-20.
11. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
12. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006;6:924-35.
13. Schnell TG, Sontag SJ, Chejfec G, et al. Longterm nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
14. Cairns J. Mutation Selection and the Natural History of Cancer. Nature 1975;255:197-200.
15. Wong DJ, Paulson TG, Prevo LJ, et al. p16 INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
16. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for future esophageal adenocarcinoma. PLoS Med 2007;4:e67.
17. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 2004;64:3414-27.
18. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000;6: 1702-10.
19. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinibresistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345-56.
20. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-9.
21. Costa DB, Schumer ST, Tenen DG, Kobayashi S. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol 2008;26:1182-4; author reply 1184-6.
22. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8.
23. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006;38: 468-73.
24. Maley CC, Galipeau PC, Li X, et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 2004;64:7629-33.
25. Thomas T, Abrams KR, De Caestecker JS, Robinson RJ. Meta analysis:Cancer risk inBarrett's oesophagus. Aliment Pharmacol Ther 2007;26:1465-77.
26. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40.
27. Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population- based study. Am J Gastroenterol 1999;94:86-91.
28. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002;122:26-33.
29. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res 2006;12:3661-97.
30. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103:788-97.
31. Sharma VK,Wang KK, Overholt BF, et al. Balloonbased, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007;65:185-95.
32. Tobey NA, Argote CM, Vanegas XC, Barlow W, Orlando RC. Electrical parameters and ion species for active transport in human esophageal stratified squamous epithelium and Barrett's specialized columnar epithelium. Am J Physiol Gastrointest Liver Physiol 2007;293:G264-70.
33. Dixon J, Strugala V, Griffin SM, et al. Esophageal mucin: an adherent mucus gel barrier is absent in the normal esophagus but present in columnarlined Barrett's esophagus. Am J Gastroenterol 2001;96:2575-83.
34. Jovov B, Van Itallie CM, Shaheen NJ, et al. Claudin-18: a dominant tight junction protein in Barrett's esophagus and likely contributor to its acid resistance. Am J Physiol Gastrointest Liver Physiol 2007;293:G1106-13.
35. Orlando RC.Sharma PSR. Mucosal Defense in Barrett's Esophagus. Barrett's Esophagus and Esophageal Adenocarcinoma 2006. Oxford (UK): Blackwell Publishing, Ltd 60-72.
36. Ostrowski J, Mikula M, Karczmarski J, et al. Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics. J Mol Med 2007;85:733-43.
37. Folkman J, Kalluri R. Cancer without Disease. Nature 2004;427:787.
38. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-98.
39. Overholt BF, Wang KK, Burdick JS, et al. Fiveyear efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007;66:460-8.
40. Vaughan TL, Dong LM, Blount PL, et al. Non- steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005;6: 945-52.